stem cell
-
Brainstorm’s ALS Data Fail to Persuade FDA Advisors, Who Vote Down the Stem Cell Therapy
NurOwn, Brainstorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.
-
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Morning Read: Unapproved stem cell tests abound, an artificial pancreas on the horizon
Also, Owlstone has spun out Owlstone Medical to develop a breathalyzer for clinical diagnostics to battle cancer and Pocket DNA sequencers will become ubiquitous, according to Dr. Eric Topol.
-
Neurona gets $23.5M for stem cell approach to neurological disease
As opposed to taking a small molecule or even antibody approach to treating neurological disease, Neurona “is focused on unique compositions of cells that can be precisely targeted, integrated into damaged neural circuits, and provide activity-dependent regulation.”
-
Belgian clinic repairs bones with new ground-breaking stem cell technique
BRUSSELS (Reuters) – Belgian medical researchers have succeeded in repairing bones using stem cells from […]